Fabre-Kramer is committed to developing and bringing to market advanced new medications to help physicians treat their patients’ unmet medical needs in the therapeutic areas of psychiatry and neurology. The Company focuses on compounds to license-in, develop for global registration, and license-out to commercial partners.
We use cookies to help give you the best experience on our site and to allow us to customise the content you see across websites to provide you with the best possible experience.
These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Privacy Policy.